CA2644649C - Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53 - Google Patents

Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53 Download PDF

Info

Publication number
CA2644649C
CA2644649C CA2644649A CA2644649A CA2644649C CA 2644649 C CA2644649 C CA 2644649C CA 2644649 A CA2644649 A CA 2644649A CA 2644649 A CA2644649 A CA 2644649A CA 2644649 C CA2644649 C CA 2644649C
Authority
CA
Canada
Prior art keywords
6alkyl
hydrogen
formula
hydroxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2644649A
Other languages
English (en)
French (fr)
Other versions
CA2644649A1 (en
Inventor
Jean Fernand Armand Lacrampe
Christophe Meyer
Bruno Schoentjes
Alain Philippe Poncelet
Camille Georges Wermuth
Bruno Giethlen
Jean-Marie Contreras
Muriel Joubert
Luc Van Hijfte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA2644649A1 publication Critical patent/CA2644649A1/en
Application granted granted Critical
Publication of CA2644649C publication Critical patent/CA2644649C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2644649A 2006-03-22 2007-03-19 Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53 Active CA2644649C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06111529.1 2006-03-22
EP06111529 2006-03-22
US78512006P 2006-03-23 2006-03-23
US60/785,120 2006-03-23
PCT/EP2007/052582 WO2007107545A1 (en) 2006-03-22 2007-03-19 Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53

Publications (2)

Publication Number Publication Date
CA2644649A1 CA2644649A1 (en) 2007-09-27
CA2644649C true CA2644649C (en) 2014-06-17

Family

ID=38110050

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2644649A Active CA2644649C (en) 2006-03-22 2007-03-19 Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53

Country Status (8)

Country Link
US (2) US8088795B2 (https=)
EP (1) EP1999126B1 (https=)
JP (1) JP5162574B2 (https=)
AT (1) ATE470665T1 (https=)
AU (1) AU2007228784B2 (https=)
CA (1) CA2644649C (https=)
DE (1) DE602007007065D1 (https=)
WO (1) WO2007107545A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
JP5438008B2 (ja) * 2007-09-21 2014-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
TWI476189B (zh) 2009-02-04 2015-03-11 Janssen Pharmaceutica Nv 用作抗癌劑之吲哚衍生物
US8658170B2 (en) 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
WO2011098262A2 (en) 2010-02-09 2011-08-18 Universität Bremen P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
CA2805658C (en) * 2010-07-21 2016-12-13 Joseph P. Errico Combination therapy with mdm2 and egfr inhibitors
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
US10016414B2 (en) * 2010-11-12 2018-07-10 University Of Massachusetts Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
CN103221094B (zh) * 2010-11-19 2016-04-20 诺华有限公司 Mdm2/4及p53相互作用抑制剂的结晶型
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
CR20170077A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
JP6564029B2 (ja) 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016181414A1 (en) * 2015-05-12 2016-11-17 Council Of Scientific & Industrial Research Process for the synthesis of ivacaftor and related compounds
DK3331876T3 (da) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma
TW202332444A (zh) * 2015-10-23 2023-08-16 日商第一三共股份有限公司 用於治療癌症之醫藥組成物
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN115650976A (zh) 2017-07-24 2023-01-31 生命医药有限责任公司 RORγ的抑制剂
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO863197A0 (en) 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
US6309492B1 (en) 1998-09-16 2001-10-30 Marc A. Seidner Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
CN1329493A (zh) 1998-12-02 2002-01-02 辉瑞产品公司 恢复p53家族蛋白质的构象稳定性的方法和组合物
DE60137435D1 (de) 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
DK1859798T3 (en) 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
WO2003040402A2 (en) * 2001-11-09 2003-05-15 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
NZ532463A (en) 2001-11-13 2007-02-23 Dimensional Pharm Inc Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
PL370823A1 (en) 2001-12-18 2005-05-30 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
GB0419481D0 (en) * 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
ATE474833T1 (de) * 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53

Also Published As

Publication number Publication date
US8377961B2 (en) 2013-02-19
US8088795B2 (en) 2012-01-03
US20120071508A1 (en) 2012-03-22
WO2007107545A1 (en) 2007-09-27
EP1999126B1 (en) 2010-06-09
AU2007228784A1 (en) 2007-09-27
JP2009530345A (ja) 2009-08-27
DE602007007065D1 (de) 2010-07-22
CA2644649A1 (en) 2007-09-27
EP1999126A1 (en) 2008-12-10
ATE470665T1 (de) 2010-06-15
JP5162574B2 (ja) 2013-03-13
US20100168163A1 (en) 2010-07-01
AU2007228784B2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
CA2644649C (en) Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
CA2644643C (en) Inhibitors of the interaction between mdm2 and p53
US7834016B2 (en) Inhibitors of the interaction between MDM2 and p53
CA2699707C (en) Inhibitors of the interaction between mdm2 and p53
EP2203440B1 (en) Inhibitors of the interaction between mdm2 and p53
CN108473471A (zh) 用作雄性激素受体拮抗剂的被取代的硫尿囊素衍生物
CN101405285B (zh) 作为mdm2和p53间相互作用的抑制剂的环状-烷基胺衍生物
BRPI0709049A2 (pt) composto inibidor da interação entre mdm2 e p53, composição farmacêutica, processo para preparar a referida composição farmacêutica, uso do composto, combinação, e processo para preparar o referido composto

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250922

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106